NCT05789901

The MARVIN Chatbots to Provide Information for Different Health Conditions

Recruiting now NA Last updated 6 March 2024

What this trial tests

NA trial testing MARVIN in HIV Infections in 400 participants. Currently enrolling.

Timeline

1 March 2024

Primary endpoint
31 December 2033

31 December 2034

Quick facts

Lead sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	400
Start date	1 March 2024
Primary completion	31 December 2033
Estimated completion	31 December 2034
Sites	2 locations across Canada

Drugs / interventions tested

• MARVIN
• MARVIN-Pharma
• MARVINA
• MARVIN-CHAMP

Conditions studied

• HIV Infections — all drugs for HIV Infections →
• Breast Cancer — all drugs for Breast Cancer →
• Pediatric Emergency Medicine — all drugs for Pediatric Emergency Medicine →

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Who can join

14 and older, any sex, with HIV Infections or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. The first AI-based Chatbot to promote HIV self-management: A mixed methods usability study.
   Ma Y, Achiche S, Tu G, Vicente S, et al · · 2025 · cited 10× · PMID 39390632 · DOI 10.1111/hiv.13720
2. Adapting and Evaluating an AI-Based Chatbot Through Patient and Stakeholder Engagement to Provide Information for Different Health Conditions: Master Protocol for an Adaptive Platform Trial (the MARVIN Chatbots Study).
   Ma Y, Achiche S, Pomey MP, Paquette J, et al · · 2024 · cited 10× · PMID 38349734 · DOI 10.2196/54668
3. Large language models in medicine: A review of current clinical trials across healthcare applications.
   Omar M, Nadkarni GN, Klang E, Glicksberg BS. · · 2024 · cited 9× · PMID 39561120 · DOI 10.1371/journal.pdig.0000662
4. Coconstructing CHAMP, an Artificial Intelligence Chatbot for Pediatric Infectious Symptoms Management: Protocol for a Multiphase Participatory Study.
   Lin J, Jaiswal N, Ma Y, Lebouché B, et al · · 2026 · PMID 42189574 · DOI 10.2196/89852